


In the Claims

Please add new claims 52-81.

Please re-write the pending claims as follows:

- D2
1. (Currently Amended) A method for treating a subject having a condition characterized by an abnormal mammalian cell proliferation, comprising:
administering to a subject in need of such treatment, a compound selected from the group consisting of an anti-angiogenic compound and an anti-cancer compound, and an agent, in an amount effective to inhibit the proliferation, wherein the agent is a compound of Formula H-III



wherein m is an integer between 0 and 10, inclusive; A and A₁ are L- or D-amino acid residues; A in each repeating bracketed unit can be a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A₁ and C, and between A₁ and N are peptide bonds; and each X₁ and X₂ is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH.

2. (Original) The method of claim 1, wherein the abnormal mammalian cell proliferation is manifested as a tumor.
3. (Original) The method of claim 1, wherein the condition is further characterized by the presence of reactive stromal fibroblasts.
4. (Original) The method of claim 1, wherein the abnormal mammalian cell proliferation is in epithelial cells.
5. (Original) The method of claim 4, wherein the abnormal mammalian cell proliferation is selected from the group consisting of a carcinoma, a sarcoma, and a melanoma.
6. (Original) The method of claim 1, wherein the condition is a metastasis of epithelial origin.

Cont D2
7. (Previously Amended) The method of claim 1, wherein the condition is selected from the group consisting of breast cancer, colorectal cancer, ovarian cancer, prostate cancer, pancreatic cancer, kidney cancer, lung cancer, melanoma and fibrosarcoma.

8. (Original) The method of claim 1, wherein the condition is selected from the group consisting of bone and connective tissue sarcomas.

9.-10. (Cancelled)

11. (Original) The method of claim 1, wherein the subject is otherwise free of symptoms calling for hemopoietic stimulation.

12. (Original) The method of claim 1, wherein the agent is administered in combination with surgery to remove an abnormal proliferative cell mass.

13. (Original) The method of claim 1, wherein the agent is administered to a patient who has had surgery to remove an abnormal proliferative cell mass.

14. (Original) The method of claim 1, wherein the agent is administered in combination with an anti-cancer compound.

15. (Original) The method of claim 1, wherein the agent is targeted to a tumor.


16. (Original) The method of claim 1, wherein the subject has normal hemopoietic activity.

17. (Original) The method of claim 1, wherein the subject is HIV negative.

18. (Original) The method of claim 1, wherein the agent is Val-boro-Pro.

19. (Currently Amended) A method for inhibiting angiogenesis in a subject having a condition characterized by abnormal mammalian cell proliferation comprising:

administering to a subject in need of such treatment, a compound selected from the group consisting of an anti-angiogenic compound and an anti-cancer compound, and an agent, in an amount effective to inhibit angiogenesis in an abnormal proliferative cell mass, wherein the agent is a compound of Formula H-III




wherein m is an integer between 0 and 10, inclusive; A and A₁ are L- or D-amino acid residues; A in each repeating bracketed unit can be a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A₁ and C, and between A₁ and N are peptide bonds; and each X₁ and X₂ is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH.

20.-30. (Cancelled)

31. (Original) The method of claim 19, wherein the agent is administered in combination with an anti-angiogenic compound.

32.-35. (Cancelled)


36. (Currently Amended) A pharmaceutical preparation comprising:
an agent of Formula H-III



wherein m is an integer between 0 and 10, inclusive; A and A₁ are L- or D-amino acid residues; A in each repeating bracketed unit can be a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A₁ and C, and between A₁ and N are peptide bonds; and each X₁ and X₂ is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH,

at least one other anti-cancer compound, and
a pharmaceutically acceptable carrier.

37. (Currently Amended) A pharmaceutical preparation comprising:
an agent of Formula H-III




wherein m is an integer between 0 and 10, inclusive; A and A₁ are L- or D-amino acid residues; A in each repeating bracketed unit can be a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A₁ and C, and between A₁ and N are peptide bonds; and each X₁ and X₂ is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH,

at least one other anti-angiogenic compound, and
a pharmaceutically acceptable carrier.

38. (Previously Added) A method for treating a subject having a condition characterized by an abnormal mammalian cell proliferation, comprising:


administering to a subject in need of such treatment, a compound selected from the group consisting of an anti-angiogenic compound and an anti-cancer compound, and an agent, in an amount effective to inhibit the proliferation, wherein the agent is a compound of Formula II



wherein m is an integer between 0 and 10, inclusive; A and A₁ are L- or D-amino acid residues; and each X₁ and X₂ is independently a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH, and wherein the condition is further characterized by the presence of reactive stromal fibroblasts.

39. (Previously Added) A method for treating a subject having a condition characterized by an abnormal mammalian cell proliferation, comprising:

administering to a subject in need of such treatment, a compound selected from the group consisting of an anti-angiogenic compound and an anti-cancer compound, and an agent, in an amount effective to inhibit the proliferation, wherein the agent is a compound of Formula II



wherein m is an integer between 0 and 10, inclusive; A and A₁ are L- or D-amino acid residues; and each X₁ and X₂ is independently a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH, and wherein the condition is selected from the group consisting of bone and connective tissue sarcomas.

40. (Currently Amended) The method of claim 1, wherein m in Formula H-III is zero.

41. (Previously Added) The method of claim 40, wherein A₁ is selected from the group consisting of valine, lysine, proline and alanine.

42. (Previously Added) The method of claim 1, wherein A and A₁ are L- or D- isomers of naturally occurring amino acid residues.

43. (Currently Amended) The method of claim 19, wherein m in Formula H-III is zero.

44. (Previously Added) The method of claim 43, wherein A₁ is selected from the group consisting of valine, lysine, proline, and alanine.

45. (Previously Added) The method of claim 19, wherein A and A₁ are L- or D- isomers of naturally occurring amino acid residues.

Cont 2
46. (Currently Amended) The pharmaceutical preparation of claim 36, wherein m in Formula H-III is zero.

47. (Previously Added) The pharmaceutical preparation of claim 46, wherein A₁ is selected from the group consisting of valine, lysine, proline and alanine.

48. (Previously Added) The pharmaceutical preparation of claim 36, wherein A and A₁ are L- or D- isomers of naturally occurring amino acid residues.

49. (Currently Amended) The pharmaceutical preparation of claim 37, wherein m in Formula H-III is zero.

50. (Previously Added) The pharmaceutical preparation of claim 49, wherein A₁ is selected from the group consisting of valine, lysine, proline, and alanine.

51. (Previously Added) The pharmaceutical preparation of claim 37, wherein A and A₁ are L- or D- isomers of naturally occurring amino acid residues.

52. (New) The method of claim 14, wherein the anti-cancer compound is wherein the anti-cancer compound is Aldesleukin, Asparaginase, Bleomycin Sulfate, Carboplatin, Chlorambucil, Cisplatin, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin hydrochloride, Docetaxel, Doxorubicin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Etoposide, Etoposide phosphate, Floxuridine, Fludarabine, Fluorouracil, Gemcitabine, Gemcitabine hydrochloride, Hydroxyurea, Idarubicin Hydrochloride, Ifosfamide, Interferons, Interferon- α 2a, Interferon- α 2b, Interferon- α n3, Interferon- γ 1b, Interleukins, Irinotecan, Mechlorethamine hydrochloride, Melphalan, Mercaptopurine, Methotrexate, Methotrexate sodium, Mitomycin, Mitoxantrone, Paclitaxel, Pegaspargase, Pentostatin, Prednisone, Profimer sodium, Procabazine Hydrochloride, Taxol, Taxotere, Teniposide, Topotecan Hydrochloride, Vinblastine Sulfate, Vincristine Sulfate or Vinorelbine tartrate.

53. (New) The method of claim 1, wherein the agent is administered in combination with an anti-angiogenic compound.

54. (New) The method of claim 53, wherein the anti-angiogenic compound is angiostatin or endostatin.


55. (New) The method of claim 31, wherein the anti-angiogenic compound is angiostatin or endostatin.

56. (New) The pharmaceutical preparation of claim 36, wherein the anti-cancer compound is Aldesleukin, Asparaginase, Bleomycin Sulfate, Carboplatin, Chlorambucil, Cisplatin, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin hydrochloride, Docetaxel, Doxorubicin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Etoposide, Etoposide phosphate, Floxuridine, Fludarabine, Fluorouracil, Gemcitabine, Gemcitabine hydrochloride, Hydroxyurea, Idarubicin Hydrochloride, Ifosfamide, Interferons, Interferon- α 2a, Interferon- α 2b, Interferon- α n3, Interferon- γ 1b, Interleukins, Irinotecan, Mechlorethamine hydrochloride, Melphalan, Mercaptopurine, Methotrexate, Methotrexate sodium, Mitomycin, Mitoxantrone, Paclitaxel, Pegaspargase, Pentostatin, Prednisone, Profimer sodium, Procabazine Hydrochloride, Taxol, Taxotere, Teniposide, Topotecan Hydrochloride, Vinblastine Sulfate, Vincristine Sulfate or Vinorelbine tartrate.

57. (New) The pharmaceutical preparation of claim 37, wherein the anti-angiogenic compound is angiostatin or endostatin.

58. (New) The method of claim 38, wherein the agent is administered in combination with an anti-cancer compound.

59. (New) The method of claim 58, wherein the anti-cancer compound is Aldesleukin, Asparaginase, Bleomycin Sulfate, Carboplatin, Chlorambucil, Cisplatin, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin hydrochloride, Docetaxel, Doxorubicin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Etoposide, Etoposide phosphate, Floxuridine, Fludarabine, Fluorouracil, Gemcitabine, Gemcitabine hydrochloride, Hydroxyurea, Idarubicin Hydrochloride, Ifosfamide, Interferons, Interferon- α 2a, Interferon- α 2b, Interferon- α n3, Interferon- γ 1b, Interleukins, Irinotecan, Mechlorethamine hydrochloride, Melphalan, Mercaptopurine, Methotrexate, Methotrexate sodium, Mitomycin,

 Mitoxantrone, Paclitaxel, Pegaspargase, Pentostatin, Prednisone, Profimer sodium, Procarbazine Hydrochloride, Taxol, Taxotere, Teniposide, Topotecan Hydrochloride, Vinblastine Sulfate, Vincristine Sulfate or Vinorelbine tartrate.

60. (New) The method of claim 38, wherein the agent is administered in combination with an anti-angiogenesis compound.

61. (New) The method of claim 60, wherein the anti-angiogenic compound is angiostatin or endostatin.

62. (New) The method of claim 39, wherein the agent is administered in combination with an anti-cancer compound.

63. (New) The method of claim 62, wherein the anti-cancer compound is Aldesleukin, Asparaginase, Bleomycin Sulfate, Carboplatin, Chlorambucil, Cisplatin, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin hydrochloride, Docetaxel, Doxorubicin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Etoposide, Etoposide phosphate, Floxuridine, Fludarabine, Fluorouracil, Gemcitabine, Gemcitabine hydrochloride, Hydroxyurea, Idarubicin Hydrochloride, Ifosfamide, Interferons, Interferon- α 2a, Interferon- α 2b, Interferon- α n3, Interferon- γ 1b, Interleukins, Irinotecan, Mechlorethamine hydrochloride, Melphalan, Mercaptopurine, Methotrexate, Methotrexate sodium, Mitomycin, Mitoxantrone, Paclitaxel, Pegaspargase, Pentostatin, Prednisone, Profimer sodium, Procarbazine Hydrochloride, Taxol, Taxotere, Teniposide, Topotecan Hydrochloride, Vinblastine Sulfate, Vincristine Sulfate or Vinorelbine tartrate.

64. (New) The method of claim 39, wherein the agent is administered in combination with an anti-angiogenesis compound.

65. (New) The method of claim 64, wherein the anti-angiogenic compound is angiostatin or endostatin.

66. (New) The method of claim 1, wherein the agent is administered locally.

67. (New) The method of claim 1, wherein the agent is administered systemically.

Cont
52
68. (New) The method of claim 19, wherein the abnormal mammalian cell proliferation is manifested as a tumor.

69. (New) The method of claim 19, wherein the abnormal mammalian cell proliferation is in epithelial cells.

70. (New) The method of claim 19, wherein the abnormal mammalian cell proliferation is selected from the group consisting of a carcinoma, a sarcoma, and a melanoma.

71. (New) The method of claim 19, wherein the condition is a metastasis.

72. (New) The method of claim 19, wherein the condition is selected from the group consisting of breast cancer, colorectal cancer, ovarian cancer, prostate cancer, pancreatic cancer, kidney cancer, lung cancer, melanoma and fibrosarcoma.

73. (New) The method of claim 19, wherein the agent is administered locally.

74. (New) The method of claim 19, wherein the agent is administered systemically.

75. (New) The method of claim 19, wherein the subject is free of symptoms calling for hemopoietic stimulation.

76. (New) The method of claim 19, wherein the agent is administered in combination with surgery to remove an abnormal proliferative cell mass.

77. (New) The method of claim 19, wherein the agent is administered to a patient who has had surgery to remove an abnormal proliferative cell mass.

78. (New) The method of claim 19, wherein the subject has normal hemopoietic activity.

79. (New) The method of claim 19, wherein the subject is HIV negative.
80. (New) The method of claim 19, wherein the agent is Val-boro-Pro.
81. (New) The method of claim 19, wherein the agent is targeted to a tumor.
-